Clinical Partners Limited, a prominent provider of mental health treatment, has successfully acquired Oxford ADHD & Autism Centre (“Oxford ADHD”), strengthening its position in the field of neurodevelopmental disorders.
As one of the largest independent providers of neurodevelopmental and mental health services in the UK, Clinical Partners serves both the NHS and private sectors. With a dedicated workforce of over 400 professionals nationwide, the company supports approximately 40,000 patients annually. This recent acquisition reflects Clinical Partners’ commitment to expanding its capacity and reaching a broader audience.
Established in 2015 by Dr Polly Branney, Oxford ADHD & Autism Centre specialises in the diagnosis and support of individuals, including children and adults, with neurodevelopmental disorders and related conditions. The clinic has a team of around 40 specialised staff members who will now join Clinical Partners.
Dr Alice Parshall, Chief Medical Officer at Clinical Partners, expressed her enthusiasm, stating, “We are thrilled to welcome the colleagues from Oxford ADHD Centre to Clinical Partners. Polly and her team have built a reputation as a trusted provider of high-quality services in the Oxford area, and we share a common goal of delivering safe and effective care. We look forward to collaborating and utilising our combined experience and expertise to further enhance our services for patients and their families.”
Dr Polly Branney shared her perspective on the acquisition, saying, “I founded the clinic eight years ago after recognising the significant gap in local provision for individuals referred for autism and ADHD. Since then, we have successfully treated over 3,000 patients and formed partnerships with various NHS services, enabling adults and children to access expert support.”
“As a small independent clinic facing increasing demand, it became evident that we could have a more substantial impact as part of a larger organisation that can invest in growth and training. Clinical Partners is the perfect match for us, and I wish everyone involved the best as Oxford ADHD embarks on its next chapter,” added Dr Branney.
The acquisition of Oxford ADHD, encompassing the entire share capital, was finalised on June 20, 2023, for an undisclosed amount. CapEQ (M&A) advised Oxford ADHD during the process, with legal advice provided by Freeths. Keystone Law advised Clinical Partners on the transaction.
Mark Sapsford, Director at CapEQ, remarked, “In today’s world, easy access to mental health support is crucial, and we are proud to have facilitated this transaction. We extend our best wishes to both parties as they combine their resources to provide even more effective support and treatment in the Thames Valley and beyond.”
Malin Svanberg Larsson, Partner at Freeths, commented, “We are delighted to have assisted Polly and the Oxford ADHD team throughout this transaction. We wish both Clinical Partners and Oxford ADHD continued success as they continue their invaluable work of providing mental health support to patients across the NHS and private sector.”